MétaCan
Menu
Back to cohort
Record W2326124506 · doi:10.1176/pn.37.16.0017a

Isolating Isomers Enhances Antidepressant Efficacy, Study Shows

2002· article· en· W2326124506 on OpenAlexaboutno aff
Jim Rosack

Bibliographic record

VenuePsychiatric News · 2002
Typearticle
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsnot available
Fundersnot available
KeywordsAntidepressantPharmacologyPsychologyChemistryComputer scienceMedicinePsychiatryAnxiety

Abstract

fetched live from OpenAlex

Back to table of contents Previous article Next article Clinical & Research NewsFull AccessIsolating Isomers Enhances Antidepressant Efficacy, Study ShowsJim RosackJim RosackPublished Online:16 Aug 2002https://doi.org/10.1176/pn.37.16.0017aTwo research reports presented at the 23rd Collegium Internationale NeuroPsychopharmacologium Congress in Montreal in June indicate that isolation of active, single forms of molecules, called isomers, from mixed-isomer compounds can yield significant improvements in efficacy and in safety and tolerability profiles.The first report, about the antidepressant escitalopram (Lexapro), which was developed in Europe by Lundbeck and licensed to Forest Laboratories for marketing in the United States, indicates that the drug is more than twice as potent at increasing brain serotonin availability as its parent compound, citalopram (Celexa). Escitalopram is the S-isomer of citalopram, which is a compound that contains two isomers—or mirror-image forms (labeled the S and R isomers)—of the same molecule.Pharmacologists are finding that more often than not, one of the two isomers in mixed compounds is much more “active” than the other isomer, and is often responsible for therapeutic action of the compound, while the second isomer is often associated with secondary drug effects, which could manifest as side effects.The second research report indicates that when escitalopram (the compound’s generic name, simply indicating the chemical name, S-citalopram, phonetically) is administered along with the R-isomer, the ability of the S-isomer to increase serotonin levels actually declines, indicating that the R-isomer may be interfering with the active S-isomer’s ability to increase serotonin availability in the brain, according to Jack Gorman, M.D., the Lieber Professor and vice chair for research at the College of Physicians and Surgeons of Columbia University, who was involved in the studies.The mechanism by which the R-isomer affects the ability of the S-isomer to boost serotonin levels is still a mystery. However, pharmacologists at Lundbeck and Forest suspect that the two isomers are competing to bind with serotonin reuptake transporters. While the S-isomer is very potent at binding to and blocking the reuptake transporter, the R-isomer binds but may not as effectively disable reuptake.Overall, clinical trial data for escitalopram have been quite favorable, showing increased potency compared with citalopram. Previous studies have indicated that the new drug also has a reduced drug-interaction profile and is well tolerated, with few significant or serious side effects.A new drug application for escitalopram was submitted to the FDA in March 2001, and the agency issued an “approvable” letter for the new drug last January. A Forest spokesperson told Psychiatric News that final approval for marketing is expected within the “very near future.” ▪ ISSUES NewArchived

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.089
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.299
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2002
Admission routes1
Has abstractyes

Explore more

Same venuePsychiatric NewsSame topicTreatment of Major DepressionFrench-language works237,207